Engineered MSC‐sEVs as a Versatile Nanoplatform for Enhanced Osteoarthritis Treatment via Targeted Elimination of Senescent Chondrocytes and Maintenance of Cartilage Matrix Metabolic Homeostasis
Top Cited Papers
Open Access
- 4 January 2025
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 12 (8) , 2413759
Abstract
Chondrocyte senescence is an important pathogenic factor causing osteoarthritis (OA) progression through persistently producing pro‐inflammatory factors. Mesenchymal stem cells‐derived small extracellular vesicles (MSC‐sEVs) have shown anti‐inflammatory effects in OA models, while persistent existence of senescent chondrocytes still promotes cartilage destruction. Therefore, improving the targeted elimination ability on senescent chondrocytes is required to facilitate the translation of MSC‐sEVs in OA treatment. In this study, versatile engineered MSC‐sEVs are developed to targetedly clear senescent chondrocytes and maintain cartilage metabolic homeostasis. Specifically, MSC‐sEVs are loaded with siRNA mouse double minute 2 homologue (siMDM2) and modified with cartilage‐targeting peptide WYRGRL‐PEG2K‐DSPE (WPD), named WPD‐sEVssiMDM2. The results demonstrate versatile modification improves the cellular uptake of MSC‐sEVs in chondrocytes, and thus improves the antiaging effects. Importantly, multifunctional modification enhances cartilage penetration ability and extends joint retention time of MSC‐sEVs. In both post‐traumatic OA mice and naturally aged mice, WPD‐sEVssiMDM2 more effectively eliminates senescent chondrocytes and maintained matrix metabolic homeostasis. By using the P53 phosphorylation inhibitor, the essential role MDM2‐P53 pathway in the antiaging function of WPD‐sEVssiMDM2 on chondrocytes is verified. In ex vivo cultured human OA cartilage explants, it is confirmed that WPD‐sEVssiMDM2 alleviates senescent phenotype. Altogether, the findings suggest that WPD‐sEVssiMDM2 have promising translational potential for OA treatment.Keywords
Funding Information
- National Natural Science Foundation of China (82072419, 82402879, 82072550)
- National Key Research and Development Program of China (2023YFC2507604, 2023YFC2507602)
This publication has 48 references indexed in Scilit:
- Control of articular degeneration by extracellular vesicles from stem/stromal cells as a potential strategy for the treatment of osteoarthritisBiochemical Pharmacology, 2024
- Inflammatory Fibroblast‐Like Synoviocyte‐Derived Exosomes Aggravate Osteoarthritis via Enhancing Macrophage GlycolysisAdvanced Science, 2024
- A Novel Cargo Delivery System‐AnCar‐ExoLaIMTS Ameliorates Arthritis via Specifically Targeting Pro‐Inflammatory MacrophagesAdvanced Science, 2023
- Melatonin Engineering M2 Macrophage‐Derived Exosomes Mediate Endoplasmic Reticulum Stress and Immune Reprogramming for Periodontitis TherapyAdvanced Science, 2023
- Targeted delivery of RNAi to cancer cells using RNA-ligand displaying exosomeActa Pharmaceutica Sinica B, 2022
- Reversing the surface charge of MSC‐derived small extracellular vesicles by εPL‐PEG‐DSPE for enhanced osteoarthritis treatmentJournal of Extracellular Vesicles, 2021
- A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosisBioactive Materials, 2021
- Cellular senescence in knee osteoarthritis: molecular mechanisms and therapeutic implicationsAgeing Research Reviews, 2021
- Cartilage-targeting peptide-modified dual-drug delivery nanoplatform with NIR laser response for osteoarthritis therapyBioactive Materials, 2021
- Embryonic Stem Cells‐Derived Exosomes Endowed with Targeting Properties as Chemotherapeutics Delivery Vehicles for Glioblastoma TherapyAdvanced Science, 2019